Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Antiviral Res. 2019 May 7;168:9–17. doi: 10.1016/j.antiviral.2019.05.001

Figure 4.

Figure 4.

Protective efficacy of the vaccine viruses against RSV A2 strain. (A) RSV A2 virus titers in lungs as determined by plaque assay in Hep2 cells. (B) Body weight loss following RSV challenge. (C) IFNγ concentration in the lungs and BAL of immunized mice post-RSV challenge. (*) indicates a significant difference between indicated groups (p<0.05, Mann-Whitney U test).